- Home
- EXPE vs NTRA Comparison
EXPE vs NTRA Comparison
Compare EXPE & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXPE
- NTRA
- Stock Information
- Founded
- EXPE 1996
- NTRA 2003
- Country
- EXPE United States
- NTRA United States
- Employees
- EXPE N/A
- NTRA N/A
- Industry
- EXPE Transportation Services
- NTRA Medical Specialities
- Sector
- EXPE Consumer Discretionary
- NTRA Health Care
- Exchange
- EXPE Nasdaq
- NTRA Nasdaq
- Market Cap
- EXPE 22.6B
- NTRA 21.9B
- IPO Year
- EXPE 1999
- NTRA 2015
- Fundamental
- Price
- EXPE $187.34
- NTRA $138.90
- Analyst Decision
- EXPE Buy
- NTRA Strong Buy
- Analyst Count
- EXPE 27
- NTRA 16
- Target Price
- EXPE $183.96
- NTRA $185.56
- AVG Volume (30 Days)
- EXPE 1.5M
- NTRA 1.3M
- Earning Date
- EXPE 08-07-2025
- NTRA 08-07-2025
- Dividend Yield
- EXPE 0.85%
- NTRA N/A
- EPS Growth
- EXPE 54.83
- NTRA N/A
- EPS
- EXPE 8.57
- NTRA N/A
- Revenue
- EXPE $13,790,000,000.00
- NTRA $1,831,000,000.00
- Revenue This Year
- EXPE $5.43
- NTRA $19.75
- Revenue Next Year
- EXPE $6.27
- NTRA $16.04
- P/E Ratio
- EXPE $21.85
- NTRA N/A
- Revenue Growth
- EXPE 5.57
- NTRA 51.50
- 52 Week Low
- EXPE $110.20
- NTRA $92.14
- 52 Week High
- EXPE $207.73
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- EXPE 62.03
- NTRA 30.96
- Support Level
- EXPE $177.00
- NTRA $136.91
- Resistance Level
- EXPE $193.79
- NTRA $142.49
- Average True Range (ATR)
- EXPE 4.39
- NTRA 5.08
- MACD
- EXPE 0.71
- NTRA -1.82
- Stochastic Oscillator
- EXPE 64.42
- NTRA 7.18
About EXPE Expedia Group Inc.
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.